Van Tuyl Christopher 4

What Happened
Christopher Van Tuyl, Chief Legal Officer of Immunovant (IMVT), reported a sale of 2,634 shares on 2026-06-18 at $35.39 per share, generating roughly $93,217. The sale was a "sell-to-cover" to satisfy tax withholding when 6,872 restricted stock units (RSUs) vested on June 16, 2026. The filing indicates this sale was mandated by the issuer and was not a discretionary trade by the reporting person.

Key Details

• Transaction date and price: 2026-06-18, 2,634 shares sold at $35.39 each (≈ $93,217 total).
• Origin of shares: Related to RSUs granted Dec 16, 2024 (109,956 RSUs total); 6,872 RSUs vested on Jun 16, 2026 (per footnote).
• Net retained from this vesting: 6,872 vested − 2,634 sold = 4,238 shares likely retained after the sell-to-cover.
• Shares owned after transaction: Not specified in this Form 4.
• Filing/Timeliness: Form 4 filed Jun 22, 2026 (within the normal reporting window for a 6/18 transaction).
• Transaction type/code: Reported as a Sale (S); footnote clarifies the sale was to cover tax withholding (sell-to-cover) and not discretionary.

Context
This was a routine sell-to-cover tied to RSU vesting — common when companies require withholding taxes by selling a portion of vested shares. Such tax-motivated sales are not generally taken as a directional signal about the insider’s view of the stock; purchases or discretionary sales are typically more informative about sentiment.